FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334647623> ?p ?o ?g. }

• W2334647623 abstract "Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) are recognized as the prototypical chemopreventive agents. However, their wide use is precluded due to significant toxicity. The search for better NSAIDs has led to generation of nitric oxide-releasing NSAIDs (NO-NSAIDs) and more recently, to a new class of hydrogen sulfide-releasing agents (HS-NSAIDs). Both of these have shown to be more potent and less toxic than their parent NSAID. However, the draw back to these compounds is their IC50 for cell growth inhibition. It is too high to make them attractive for development as pharmaceuticals. Therefore, we postulated that a new hybrid that incorporated the active parts of each compound may be more potent and effective than either one. Our hypothesis has proved to be correct. Here we describe the effects of a nitric oxide- and hydrogen sulfide-releasing aspirin (NOSH-aspirin) on the growth properties of several human colon cancer cell lines, on induction of reactive oxygen species (ROS), and on NF-κB whose induction is strongly implicated in some cancers. Methods: NOSH-aspirin was synthesized and purified at our lab with 1H-NMR verification. Colon cancer cell lines: HT-29, HCT 15, and SW480; Cell growth: MTT; Cell cycle phase distribution: Flow cytometry; Apoptosis: subdiploid (sub-G0/G1) peak in DNA content histograms; Proliferation: PCNA; NF-kB: enzyme-linked immunosorbent assay (ELISA); Reactive oxygen species (ROS): 2′,7′-dichlorodihydrofluorescein (H2DCFDA, probe for peroxides) or dihydroethidium (DHE, probe for superoxide anion) measured fluorescence by flow cytometry. Results: NOSH-aspirin inhibited the growth of HT-29, HCT 15, and SW480 cells with IC50 values of 48 ± 3, 50 ± 5, and 60 ± 4 nM at 24 hr, respectively. The corresponding IC50 for aspirin in all 3 cell lines was >5000 µM. This represents and enhanced potency of >80,000-fold in the 3 cell lines at 24 h. NOSH-aspirin treatment of HT-29 cells at 0.5xIC50, 1xIC50, and 2xIC50 for 24 hrs induced apoptosis (20 ± 1%, 52 ± 3%, 75 ± 3%), inhibited proliferation (PCNA, 70 ± 3%, 45 ± 4%, 22 ± 3%), and caused a G0/G1 cell cycle block. Activation of NF-κB was inhibited as demonstrated by ELISA, at 0.5xIC50, 1xIC50, and 2xIC50 the reduction was 11 ± 1%, 33 ± 2%, and 46 ± 3% respectively. NOSH-aspirin caused induction of oxidative stress as evidenced by increases in both H2DCFDA and DHE-derived fluorescence representing increases in intracellular levels of H2O2 and superoxide anion respectively Conclusions: NOSH-aspirin by inducing ROS is a potent inhibitor of colon cancer cell growth and it inhibits NF-κB activation. These data suggest that NOSH-aspirin may be useful as a chemopreventive agent against colon cancer and merits further evaluation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3891. doi:1538-7445.AM2012-3891" @default.
• W2334647623 created "2016-06-24" @default.
• W2334647623 creator A5044785775 @default.
• W2334647623 creator A5048161268 @default.
• W2334647623 creator A5063551741 @default.
• W2334647623 creator A5082737345 @default.
• W2334647623 date "2012-04-15" @default.
• W2334647623 modified "2023-09-26" @default.
• W2334647623 title "Abstract 3891: NOSH-aspirin, a novel nitric oxide- and hydrogen sulfide-releasing hybrid, is a potent inhibitor of colon cancer cell growth" @default.
• W2334647623 doi "https://doi.org/10.1158/1538-7445.am2012-3891" @default.
• W2334647623 hasPublicationYear "2012" @default.
• W2334647623 type Work @default.
• W2334647623 sameAs 2334647623 @default.
• W2334647623 citedByCount "1" @default.
• W2334647623 countsByYear W23346476232019 @default.
• W2334647623 crossrefType "proceedings-article" @default.
• W2334647623 hasAuthorship W2334647623A5044785775 @default.
• W2334647623 hasAuthorship W2334647623A5048161268 @default.
• W2334647623 hasAuthorship W2334647623A5063551741 @default.
• W2334647623 hasAuthorship W2334647623A5082737345 @default.
• W2334647623 hasConcept C153911025 @default.
• W2334647623 hasConcept C178790620 @default.
• W2334647623 hasConcept C181199279 @default.
• W2334647623 hasConcept C185592680 @default.
• W2334647623 hasConcept C190283241 @default.
• W2334647623 hasConcept C2777628954 @default.
• W2334647623 hasConcept C2779707156 @default.
• W2334647623 hasConcept C2780795997 @default.
• W2334647623 hasConcept C48349386 @default.
• W2334647623 hasConcept C519581460 @default.
• W2334647623 hasConcept C553184892 @default.
• W2334647623 hasConcept C55493867 @default.
• W2334647623 hasConcept C62112901 @default.
• W2334647623 hasConcept C71924100 @default.
• W2334647623 hasConcept C86803240 @default.
• W2334647623 hasConcept C98274493 @default.
• W2334647623 hasConceptScore W2334647623C153911025 @default.
• W2334647623 hasConceptScore W2334647623C178790620 @default.
• W2334647623 hasConceptScore W2334647623C181199279 @default.
• W2334647623 hasConceptScore W2334647623C185592680 @default.
• W2334647623 hasConceptScore W2334647623C190283241 @default.
• W2334647623 hasConceptScore W2334647623C2777628954 @default.
• W2334647623 hasConceptScore W2334647623C2779707156 @default.
• W2334647623 hasConceptScore W2334647623C2780795997 @default.
• W2334647623 hasConceptScore W2334647623C48349386 @default.
• W2334647623 hasConceptScore W2334647623C519581460 @default.
• W2334647623 hasConceptScore W2334647623C553184892 @default.
• W2334647623 hasConceptScore W2334647623C55493867 @default.
• W2334647623 hasConceptScore W2334647623C62112901 @default.
• W2334647623 hasConceptScore W2334647623C71924100 @default.
• W2334647623 hasConceptScore W2334647623C86803240 @default.
• W2334647623 hasConceptScore W2334647623C98274493 @default.
• W2334647623 hasLocation W23346476231 @default.
• W2334647623 hasOpenAccess W2334647623 @default.
• W2334647623 hasPrimaryLocation W23346476231 @default.
• W2334647623 hasRelatedWork W1978183314 @default.
• W2334647623 hasRelatedWork W2019574615 @default.
• W2334647623 hasRelatedWork W2051768235 @default.
• W2334647623 hasRelatedWork W2064997073 @default.
• W2334647623 hasRelatedWork W2098971766 @default.
• W2334647623 hasRelatedWork W2108108858 @default.
• W2334647623 hasRelatedWork W2142369892 @default.
• W2334647623 hasRelatedWork W2166137593 @default.
• W2334647623 hasRelatedWork W2171914962 @default.
• W2334647623 hasRelatedWork W2185425115 @default.
• W2334647623 hasRelatedWork W2186542643 @default.
• W2334647623 hasRelatedWork W2211260210 @default.
• W2334647623 hasRelatedWork W2293689869 @default.
• W2334647623 hasRelatedWork W2303847185 @default.
• W2334647623 hasRelatedWork W2794028627 @default.
• W2334647623 hasRelatedWork W2885424915 @default.
• W2334647623 hasRelatedWork W2969697157 @default.
• W2334647623 hasRelatedWork W3082917762 @default.
• W2334647623 hasRelatedWork W3117345554 @default.
• W2334647623 hasRelatedWork W2529920633 @default.
• W2334647623 isParatext "false" @default.
• W2334647623 isRetracted "false" @default.
• W2334647623 magId "2334647623" @default.
• W2334647623 workType "article" @default.